featured-image

AlexLMX/iStock via Getty Images Jaguar Health ( NASDAQ: JAGX ) shares traded lower on Wednesday after the plant-based drug developer said data from its pivotal Phase 3 trial for anti-diarrheal medication crofelemer would be available on or before July 23, 2024. The study, named OnTarget, is designed to evaluate crofelemer (versus placebo) as a preventative treatment for cancer therapy-related diarrhea in adults with solid tumors. “The third-party vendors who are conducting the analysis of patient data for the OnTarget trial have identified the key necessary steps required to share results with Jaguar on or before July 23, allowing us to set a date for the findings,” CEO Lisa Conte remarked.

Additional updates from Jaguar’s ( JAGX ) cancer supportive care portfolio are also expected in the investor event the company plans to conduct to release Crofelemer data. In May, with its Q1 2024 results, Jaguar ( JAGX ) said topline results from OnTarget could be “imminent.” More on Jaguar Health Jaguar Health, Inc.



(JAGX) Q1 2024 Earnings Call Transcript Jaguar Health, Inc. (JAGX) Q4 2023 Earnings Call Transcript Jaguar Health extends losses as reverse stock split takes effect Jaguar stock rallies 54% on licensing deal for chemo support drug Seeking Alpha’s Quant Rating on Jaguar Health.

Back to Health Page